PDX INSIGHTS
PIONEERING CANCER RESEARCH
Model Details

Patient Information for Model: BCM-PDAC-29


Patient Information
Clinical Timeline


Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection

Model Information for Model: BCM-PDAC-29

Model Details - Initial Implantation of Patient Tissue
Mutations (Cancer Gene Census List)

GeneChrStartEndRefAltcDNA ChangeCodon ChangeProtein ChangeTVAF Gene Mutation Freq. Site Mutation Freq.Most Severe EffectAll EffectsMutation ImpactTranscript IDClinVar Clinical SignificanceCOSMIC IDgnomAD Non-Cancer AFdbSNP IDGene Mutation Freq.Site Mutation Freq.Transcript IDClinVar Clinical SignificanceCOSMIC IDdbSNP ID
AFF3chr29959387299593873CGCc.1863delgcC/gcp.D623Tfs*480.46684Frameshift MutationFrameshift MutationHIGHENST00000409579.5

COSV57841232
rs201754690
84ENST00000409579.5COSV57841232rs201754690
AKAP9chr79202286492022864AAAACc.4004_4006dupaaa/aAACaap.K1335_L1336insQ0.7741513In-frame InsertionIn-frame InsertionMODERATEENST00000356239.8

COSV62337888
rs10644111
1513ENST00000356239.8COSV62337888rs10644111
ARchrX6754531667545316TTGCAGCAGCAc.231_239dupctg/ctGCAGCAGCAgp.Q78_Q80dup0.72173In-frame InsertionIn-frame InsertionMODERATEENST00000374690.9

COSV105309998

173ENST00000374690.9COSV105309998
ARID1Achr12677928326779283GCc.5385G>CaaG/aaCp.K1795N0.55123Missense VariantMissense VariantMODERATEENST00000324856.13

COSV61388346
0.000025336300rs200221564
123ENST00000324856.13COSV61388346rs200221564
ATMchr11108256249108256249GAc.2159G>AcGt/cAtp.R720H0.355123Missense VariantMissense VariantMODERATEENST00000278616.8
Uncertain_significance
COSV99592647
0.000050739500rs55830714
123ENST00000278616.8Uncertain_significanceCOSV99592647rs55830714
ATRXchrX7768247177682471CGc.2785G>CGag/Cagp.E929Q0.9992020Missense VariantMissense VariantMODERATEENST00000373344.10
Benign

rs3088074
2020ENST00000373344.10Benignrs3088074
AXIN1chr16288189288189CTc.2522G>AcGa/cAap.R841Q0.51433Missense VariantMissense VariantMODERATEENST00000262320.8
Benign
COSV51989077
0.008448000000rs34015754
33ENST00000262320.8BenignCOSV51989077rs34015754
BCRchr222325386223253862GAc.1343G>AcGg/cAgp.R448Q0.50373Missense VariantMissense VariantMODERATEENST00000305877.13


0.000093353200rs370367734
73ENST00000305877.13rs370367734
CIITAchr161090907010909070AGc.2702A>GcAg/cGgp.Q901R0.9812424Missense VariantMissense VariantMODERATEENST00000618327.4
Benign

0.983235000000rs7197779
2424ENST00000618327.4Benignrs7197779
DCCchr185234085452340854TCc.67T>CTtc/Ctcp.F23L0.965Missense VariantMissense VariantMODERATEENST00000442544.7
Benign

0.985567000000rs9951523
65ENST00000442544.7Benignrs9951523
DDB2chr114723817747238177GAc.1228G>AGca/Acap.A410T0.20555Missense VariantMissense VariantMODERATEENST00000256996.9
Conflicting_interpretations_of_pathogenicity
COSV104563756
0.002523310000rs143049891
55ENST00000256996.9Conflicting_interpretations_of_pathogenicityCOSV104563756rs143049891
EPHA3chr38934098489340984TCc.883T>CTct/Cctp.S295P0.26433Missense VariantMissense VariantMODERATEENST00000336596.7



33ENST00000336596.7
ERCC2chr194535166145351661TGc.2251A>CAag/Cagp.K751Q0.9781615Missense VariantMissense VariantMODERATEENST00000391945.10
Benign/Likely_benign
COSV67266431
0.322955000000rs13181
1615ENST00000391945.10Benign/Likely_benignCOSV67266431rs13181
ERCC4chr161392018213920182CAc.17C>AcCg/cAgp.P6Q0.57873Missense VariantMissense VariantMODERATEENST00000311895.8



73ENST00000311895.8
EZH2chr7148828812148828812CGc.553G>CGac/Cacp.D185H0.974119Missense VariantMissense VariantMODERATEENST00000320356.7
Benign
COSV57449162
0.078149200000rs2302427
119ENST00000320356.7BenignCOSV57449162rs2302427
CNV


Histology Information for Model: BCM-PDAC-29
There are no histology images for this model.













Metastasis Information for Model: BCM-PDAC-29
 
Patient
PDX
Liver
Local recurrence
Lung
Rectum
lymph node

Patient Treatment Information for Model: BCM-PDAC-29

Event IdTreatmentTreatment SettingAge at StartAge at EndDurationClinical ResponseReason Stopped
10Gemcitabine/capecitabineAdjuvant65.6165.92113 daysComplete Response (CR); "No evidence of disease" Completed regimen
15chemo/radiation Adjuvant66.0366.1336 daysComplete Response (CR); "No evidence of disease" Completed regimen
20Gemcitabine/AbraxaneAdjuvant67.1767.2322 daysStopped due to side effects
25Gemcitabine Adjuvant67.3467.3815 daysProgressive Disease (PD)Stopped due to disease progression
30Gemcitabine/Capecitabine Adjuvant67.4467.6784 daysUnknownCompleted regimen